CStone Pharma raises $150 million to focus on addressing specific needs of Chinese patients

China-based biopharma firm CStone Pharmaceuticals says it has closed its Series A round of $150 million dollars financing (about 975 million renminbi). Three prestigious investment companies in the industry, Oriza Seed Venture Capital (Oriza Seed), Boyu Capital, and WuXi Healthcare Ventures (WXHV), jointly invested in the round.

Founded in Shanghai and Suzhou, CStone is an innovative, research-based, bio-pharmaceutical company. Its leadership team have all served in the management of leading multi-national pharmaceutical companies.

With an overarching commitment to meeting the most pressing needs of Chinese patients, the company's pipeline covers five therapeutic areas, including oncology, cardiovascular diseases, rheumatoid arthritis, hematology and autoimmune diseases. With immuno-oncology as CStone's core therapeutic focus, the company strives to lead Chinese research to the global market through its world class R&D team, its innovative portfolio, and an open innovation strategy. The funds raised will be used to help accelerate multiple programs of the company into the clinical stage while at the same time seeking out new innovations from around the world for patients in China, and ultimately worldwide.